A Phase 3, Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ Passage Extension 34 (PE34) Process Administered Concomitantly With M-M-R™ II
Phase of Trial: Phase III
Latest Information Update: 16 Dec 2017
At a glance
- Drugs Varicella zoster virus vaccine live (Primary) ; Measles mumps and rubella virus vaccine
- Indications Varicella zoster virus infections
- Focus Pharmacodynamics
- Sponsors Merck Sharp & Dohme
- 22 Oct 2017 Status changed from not yet recruiting to recruiting.
- 05 Sep 2017 Planned initiation date changed from 6 Oct 2017 to 18 Oct 2017.
- 17 Aug 2017 Planned End Date changed from 19 Mar 2019 to 19 Apr 2019.